Phase 4 N=1,423 The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Absolute Change From Baseline in Haemoglobin A1c (HbA1c) — -1.19; -1.59; -1.61 (%)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=62 Study of Low Level Laser Therapy to Treat Low Back Pain
Low Back Pain
Primary: Difference in the Proportion of Primary Outcome Successes Between Treatment Groups — 27; 9 participants — p=<0.00001
N/A N=48 The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study
Hearing Impairment
Primary: Change in Mean Aided Word Recognition Scores (WRS) When Compared to the Baseline Unaided Condition. — 37.6 percentage of words correctly identified — p=<0.0001
N/A N=512 Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia
HIV · AIDS · Medication Adherence
Primary: Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure) — 142; 139; 6; 12 participants
N/A N=54 Study of Low Level Laser Light Therapy on Circumference Reduction
Circumference Reduction
Primary: Change in Combined Circumference Measurements — -5.36 inches — p=<.0001
Phase 4 N=41 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
Anorexia Nervosa
Primary: Change in Eating Disorder Inventory-2 Drive for Thinness Subscale (DT) — 1.36; 3.93 units on a scale
N/A N=62 Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).
Smoking
Primary: Maximum Concentration (Cmax) of Nicotine Following Single Use of mTHS, mCC and NRT — 10.70; 12.09; 7.64; 7.52 ng/mL
Phase 2 N=63 Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Rate as Per Investigator Local Review Measured Using RECIST 1.1 of Patients at Week 12 — 23.3; 20.0 Percentage of participants
N/A N=51 A Pilot Study of Early Expulsion Rates of the IUB™ SCu380A
Contraception
Primary: Expulsion Rate — 9 participants
Phase 4 N=57 Loop Diuretics Administration and Acute Heart Failure
Acute Heart Failure
Primary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04
Phase 2 N=26 Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival (PFS) Time — 82 days
Phase 1 N=26 Co-Administration of MK-4618 With Antihypertensive Agents (MK-4618-010)
Hypertension
Primary: Percentage of Participants With a Clinical or Laboratory Adverse Experience — 33.3; 53.8; 41.7; 61.5 Percentage of participants
Phase 3 N=300 Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)
Symptomatic Gastroesophageal Reflux Disease (sGERD)
Primary: Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4 — 21.23; 41.14 Percentage of Days
Phase 2 N=186 REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants
Phase 2 N=23 Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Glioma · Low-grade Glioma · Astrocytoma
Primary: Overall Response — 2; 21 participants